Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Allen Furlan who wrote (613)	5/12/1998 1:51:00 PM
From: Rocketman	Read Replies (1) \| Respond to of 3202

Your assumption is wrong. INCY has produced many, many times more sequence data than exists in the public domain. They have also developed extensive bioinformatics software to deal with this information. Their software uses not only their proprietary sequence data (and other relevant data, such as clinical info on the DNA source) but also links to the public data so that their clients can look at all of it simultaneously. To give you an idea of how far behind the public project is, they still project only 60,000 - 80,000 human genes. INCY had identified more than 80,000 genes years ago. INCY estimates the total number of human genes at 100,000 - 150,000. In terms of quantities, there is no comparison between INCY and the public domain data, and INCY is sequencing at so much faster of a rate, that the gap just keeps widening. You are right in that INCY is a service company. They service the pharmaceutical industry by providing a broad platform of genomic products and services. The vast majority of their revenue is from the database subscriptions, while relatively little of it is from things such as database administration, training, etc.... However, INCY doesn't reveal financial details except on a macro level. Their 1997 annual report is out. Call them up and order a copy: 650/855-0555 Rman Rman